Endocrine therapy remains a backbone of adjuvant therapy for women with hormone receptor–positive early-stage breast cancer. Numerous studies have demonstrated the benefit of ovarian function ...
Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10–11-day dosing intervals for women with early-stage breast cancer This is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback